VitaSpring Biomedical Co. Ltd.
Cash Flow Statement
| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-155.8K | $-75.8K | $-81.5K | $-142.5K | $-110.8K | $-80.5K | $-143.1K | $-196.3K |
| Depreciation & Amortization | — | $2.5K | — | $2.5K | $2.5K | $2.5K | $2.5K | $2.5K |
| Depreciation | — | — | $2.5K | $2.5K | $2.5K | $2.5K | $2.5K | $2.5K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | $0 | $0 | $0 | $0 | $0 | $27.5K |
| Net Cash from Operating Activities | $5.2K | $6.1K | $124 | $-839 | $-1.2K | $-787 | $-1.8K | $-6.4K |
| Investing Activities | ||||||||
| Capital Expenditures | — | — | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | — | — | — | — | — | — | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $0 | $0 | $0 | $2.0K | $2.0K | $515 | $0 | $3.0K |
| Net Change in Cash | — | — | — | — | — | — | — | — |
| Free Cash Flow | — | — | — | — | — | — | — | — |